The current status of docetaxel for advanced non-small cell lung cancer

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Green, M R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Irinotecan; NSCLC; Paclitaxel; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE;

CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 0035061760     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Docetaxel in the management of advanced nonsmall cell lung cancer
2. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer
3. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: A Japanese cooperative study
4. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer
5. Single agent docetaxel in patients with refractory non-small cell lung cancer
6. Phase II trials of Taxotere with non-small cell lung cancer
7. Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: A confirmation of prolonged survival in a multicenter trial
8. Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC
9. A prospective randomized trial of docetaxel (Taxotere®) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
10. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
11. A multicenter, randomized, phase III study of docetaxel plus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable non-small cell lung cancer (NSCLC)
12. Weekly administration of docetaxel (Taxotere): Summary of clinical data
13. Phase II trial of weekly docetaxel (D) in second-line non-small cell lung cancer (NSCLC)
14. Defining the dose of docetaxel (Taxotere) in combination chemotherapy of non-small cell lung cancer: Preserving the efficacy with lower dose regimens
15. Multicenter phase II study of docetaxel and cisplatin combination in patients with non-small cell lung cancer
16. First-line treatment of non-small cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
17. Docetaxel (Taxotere) plus cisplatin: An active alternative and well tolerated combination in patients with advanced non-small cell lung cancer
18. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer
19. First line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
20. Phase II study of docetaxel plus cisplatin in a circardian timing as first line chemotherapy in advanced non small cell lung cancer
21. Interim analysis of a phase II study of docetaxel (Taxotere) in combination with cisplatin in Korean patients with metastatic (stage IV) or unresected (stage IIIB) localized non-small cell lung cancer
22. Outpatient Taxotere/ carboplatin (T/C) combination therapy in NSCLC for induction in stage IIIB and palliation in stage IV
23. Docetaxel (Taxotere) and carboplatin in the treatment of advanced non-small cell lung cancer
24. Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer
25. Docetaxel/carboplatin combination therapy for stage IIIB/IV non-small cell lung cancer
26. Phase II trial of docetaxel and carboplatin in advanced non-small cell lung cancer
27. A randomized phase III trial of four chemotherapeutic regimens in advanced non-small cell lung cancer (NSCLC)
28. Phase I dose-finding and pharmocokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors
29. A Phase I study of sequential irinotecan and docetaxel in patients with advanced solid tumors
30. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
31. Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetaxel (DOC) in patients (pts) with non-small cell lung cancer (NSCLC): A phase II study
32. Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy in patients with metastatic non-small cell lung cancer
33. Phase I study of docetaxel and gemcitabine combination chemotherapy in chemotherapy naive patients with advanced or metastatic non-small cell lung cancer
34. Combination of docetaxel and gemcitabine in the treatment of advanced non-small cell lung cancer
35. Phase I and pharmocokinetic study of docetaxel and gemcitabine in patients with non-small cell lung cancer
36. Docetaxel and gemcitabine combinations in non-small cell lung cancer
37. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer (NSCLC): Preliminary results
38. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
39. Phase I/II evaluation of escalating dose docetaxel (Taxotere, T), Ifosfamide (I) and cisplatin (C) with Lenograstin (L) support, in patients with stage III/IV non-small cell lung cancer (NSCLCa): An Irish Clinical Oncology Research Group (ICORG) study
40. Combination chemotherapy with carboplatin, docetaxel and gemcitabine in advanced non-small cell lung cancer: A phase II study
41. Induction chemotherapy with gemcitabine, docetaxel, and cisplatin (GDP) in patients with non-small cell lung cancer (NSCLC)